

HCL Technologies | ADD

Back on track

HCLT's 2Q performance ticked most boxes. Revenues grew 2.4% cc QoQ, beating JMFfe: 1.2%. Growth construct was better too with core Services segment (+2.5% cc QoQ; JMFfe) driving the beat. Even in Software, growth was stronger in annuity revenues (Subs/Support) even as lumpy perpetual licenses dragged. Despite the mix (lower software), margins were better (17.4% vs JMFfe: 17.1%). Deal wins were higher (Net new: USD 2.6bn; +16% YoY) and granular (no mega deals). Advance AI revenues, disclosed for the first time, are clocking USD 400mn ARR. HCL is doubling down on its AI proposition (AI Force/AI Factory) with strengthened GTM, AI advisory and expanded partnership ecosystem. These are helping HCL win deals, though at the expense of revenue deflation in core services at times. HCLT's confidence of stepping up its quarterly net new TCV run-rate to USD 2.5bn+ (from USD 2bn) should offset this deflation. We will however seek more consistent TCV print to build growth acceleration. Besides, modest ask rate (0.3-1.5% CQGR in 2HFY26 for Services), lag between TCV pick-up and revenue conversion and unchanged consol. revenue guidance (3-5%) limit changes to our FY26-28E revenues. Moreover, increase R&D spend (on IPs) and mix change (lower Software) offset 2Q beat on margins. Our FY26-27E EPS is therefore little changed. HCLT is leveraging its strengths in engineering, infrastructure and software to make good strides in AI-centred services. Those should help it navigate AI's deflationary impact better than peers, in our view. 8% upmove since [our upgrade](#) and limited earnings upgrade however limit upside. We retain Add.

- **2QFY26- Strong well rounded performance:** HCLT's 2QFY26 topline beat expectations. Revenue grew 2.4% cc QoQ vs. JMFfe/Cons. est. of 1.2%/1.5%. IT and Business Services was strong (2.6% cc QoQ) – Lifesciences and healthcare/Public services led with 4.4%/7.8% QoQ growth (USD). Products and platforms growth was soft at 0.5% cc QoQ (-3.7% YoY) offsetting some of the strength in services. Softness in products was due to decline in perpetual license revenue as the company shifts its focus towards subscription. EBIT margins expanded 116 bps QoQ to 17.4% vs JMFfe/Cons. est. of 17.1%. Increased margins in software (+30bps), absence of one-off impact (+30bps), higher utilization (+50bps), FX (+56bps) aided margins partially offset by restructuring (-55bps). PAT came in at INR 42.4bn, marginally missing expectations (vs JMFfe/Cons. est. of INR 43.2/43bn). LTM FCF/PAT was 125%.
- **Guidance-Unchanged:** HCL won USD 2.57bn net new TCV, +16% YoY. LTM TCV grew at 13% YoY. The company closed two of the large deals which spilled over from Q1, thus exceeding USD 2.5bn mark without any mega deal. HCLT maintained its FY26 cc guidance for total revenue (3-5%) and raised the lower end of the guidance for services from 3-5% to 4-5%. Guidance implies CQGR of 0.3-1.5% for Services through 3Q-4QFY26. Confidence in the closed bookings, along with a strong pipeline, is informing management's guidance. The company maintained its EBIT margin guidance at 17-18%. Q3/Q4 is expected to see 70-80bps/40-50bps impact due to wage revisions. Restructuring expenses are expected to continue in Q3 and might spill into Q4. Restructuring led margin gains could be offset by higher investments, therefore margin rebound in FY27 could be limited, in our view.
- **Minimal changes in estimates; Maintain ADD:** We have revised our revenue estimates by (49)-45bps over FY26-28E. Services and ER&D revenue estimates have been increased while products' has seen a decrease. Our EBITDA margin estimates are unchanged despite 2Q beat. We expect higher R&D spend – as the company invests in IPs – and mix change (lower software) could impact margins. Our EPS has been revised by (0.7%)-2.1%. Maintain ADD.



Abhishek Kumar

abhishek.kumar@jmfll.com | Tel: (91 22) 66303053

Nandan Arekal

nandan.arekal@jmfll.com | Tel: (91 22) 62243683

Anushree Rustagi

anushree.rustagi@jmfll.com | Tel: (91 22) 69703668

Recommendation and Price Target

Current Reco.	ADD
Previous Reco.	ADD
Current Price Target (12M)	1,580
Upside/(Downside)	5.7%
Previous Price Target	1,550
Change	1.9%

Key Data – HCLT IN

Current Market Price	INR1,495
Market cap (bn)	INR4,056.1/US\$45.7
Free Float	32%
Shares in issue (mn)	2,713.7
Diluted share (mn)	2,713.7
3-mon avg daily val (mn)	INR4,927.5/US\$55.6
52-week range	2,005/1,303
Sensex/Nifty	82,327/25,227
INR/US\$	88.7

Price Performance

%	1M	6M	12M
Absolute	1.9	7.5	-18.5
Relative*	1.4	-1.9	-18.8

* To the BSE Sensex

Financial Summary

(INR mn)

Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	10,99,130	11,70,550	12,87,948	13,76,896	14,80,134
Sales Growth	8.3%	6.5%	10.0%	6.9%	7.5%
EBITDA	2,42,000	2,55,050	2,66,434	2,86,848	3,11,903
EBITDA Margin	22.0%	21.8%	20.7%	20.8%	21.1%
Adjusted Net Profit	1,57,020	1,73,910	1,74,591	1,93,652	2,12,455
Diluted EPS (INR)	57.9	64.1	64.3	71.4	78.3
Diluted EPS Growth	5.7%	10.8%	0.4%	10.9%	9.7%
ROIC	34.6%	38.5%	40.4%	44.0%	49.2%
ROE	23.5%	25.2%	24.9%	27.5%	30.1%
P/E (x)	25.8	23.3	23.2	20.9	19.1
P/B (x)	5.9	5.8	5.8	5.8	5.8
EV/EBITDA (x)	15.7	14.8	14.2	13.2	12.1
Dividend Yield	3.5%	4.0%	4.1%	4.8%	5.2%

Source: Company data, JM Financial. Note: Valuations as of 13/Oct/2025

JM Financial Research is also available on: Bloomberg - JMFR <GO>, FactSet, LSEG and S&P Capital IQ.

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

Key Highlights from the call

- **Demand:** HCLT reported broad-based demand in Q2 FY26, with growth visible across all major verticals and geographies. Management mentioned that the overall demand environment remains good, and growth this quarter was led by services. Leadership highlighted sustained client focus on legacy and application modernization and GenAI-led transformation. They also saw USD 100mn+ in advanced-AI-revenue in Q2. They noted that while the external environment continues to be unpredictable, their key business indicators like revenue growth, booking, pipeline, AI demand, etc. all look promising.
- **Outlook:** HCLT maintained its FY26 revenue growth guidance of 3–5% in cc terms, with services expected to grow 4–5% on the back of this standout quarter. Management reiterated EBIT margin guidance at 17–18%. Leadership said the company's progress in AI gives confidence in its overall AI proposition and announced plans to continue investing in advanced AI capabilities. Moreover, the company maintained that the impact of recent H-1B related developments is minimal given its low visa dependence and strong local hiring focus. Overall, management expressed confidence in achieving FY26 guidance supported by steady deal momentum, AI-led opportunities, and operational discipline.
- **Bookings:** They reported strong new bookings of USD 2.6bn in Q2 FY26 including two large deals. The company highlighted that this was the first quarter where this figure surpassed the USD 2.5bn mark without any mega deals. Management noted that this performance was broad-based across verticals and geographies. Leadership mentioned that within the top 10 renewals, five clients increased their overall ACV, while the remaining ones had a decline due to AI-linked productivity. Management added that the company continues to see a strong correlation between new bookings and revenue growth, typically with a one-two quarter lag. They also noted that the pipeline remains at a record high.
- **Margin:** EBIT margin for Q2 stood at 17.5%, expanding 116bps QoQ. The margin bridge includes – Tailwinds: +56bps from forex gains, +35bps from improved profitability of the software segment, and +81bps from services growth (+50bps from higher utilization through Project Ascend and +30bps from the absence of Q1 one-off), partially offset by, headwind: -55bps impact from restructuring charges. Management reiterated full-year EBIT margin guidance of 17–18%, while cautioning that wage revisions will weigh on margins in Q3 (70-80bps) and Q4 (incremental 40-50bps). They highlighted that the ongoing restructuring program is expected to continue through Q3 FY26 and expect a spillover in Q4 FY26 (full-year 40bps impact). Leadership emphasized that impact of the restructuring and wage revision has been baked into their guidance.
- **Segments:** Management highlighted that they have been growing in three large verticals – BFSI, Technology, and Telecom & Media. They noted that while their top performing verticals on a sequential basis were Life Sciences & Healthcare and public services, on a YoY basis Financial Services and Technology fared well. **Retail and CPG** – They highlighted that clients are showing interest in their approach to adopting and scaling AI. A couple of areas where they saw this included integration work in M&A and large scale SDLC transformation work supported by GenAI, especially their AI Force platform. **Manufacturing** – They noted that while the broader manufacturing segment is doing fine, there is continued impact due to the auto sector slowdown within the overall manufacturing vertical.
- **Advanced AI strategy:** HCLT articulated their AI strategy around four pillars – (i) proactively transforming their existing services by embedding GenAI into delivery and internal operations; (ii) building differentiated IP and AI-native solutions, where the company continues to develop proprietary accelerators, frameworks, and domain-specific assets that can be scaled across clients and industries; (iii) expanding into new AI-led services including advisory, model training, and AI operations management, with a focus on helping enterprises operationalize GenAI at scale; and (iv) strengthening the ecosystem of AI partnerships, deepening alliances with hyperscalers, foundation model providers, and start-ups to jointly build and deploy enterprise-grade AI solutions.
- **Supply:** HCLT noted continued non-linearity between revenue and headcount growth in Q2 FY26, with a 1.8% YoY increase in revenue per employee. Management said this improvement reflects efficiency gains from embedding AI across delivery and operations. The company continues to train employees at scale under its AI skill standardization framework, building black-belt cohorts across technology streams to strengthen readiness for AI-led delivery.

FY26 overall growth guidance maintained at 3-5% in cc terms,

FY26 services growth guidance at 4-5% in cc terms

Margin walk:

EBIT margins increased 116bps in 2Q.

This was driven by-

Forex gains: +56bps,

Software growth: +35bps,

Services growth: +80bps, and

Restructuring charges: -55bps

Exhibit 1. 2QFY26 result summary

	2Q26 A	1Q26 A	Change (QoQ)	Estimate (JMFe)	Variance (vs. JMFe)	Estimate (Consensus)	Variance (vs. consensus)	QoQ estimate	
								JMFe	Consensus
USD-INR	87.66	85.61	2.4%	87.99	-0.4%	87.58	0.1%	2.8%	2.3%
CC Revenue Growth (QoQ)	2.4%	-0.8%		1.2%		1.5%		1.2%	1.5%
Revenue (USD mn)	3,644	3,545	2.8%	3,601	1.2%	3,612	0.9%	1.6%	1.9%
Revenue (INR mn)	319,420	303,490	5.2%	316,875	0.8%	316,321	1.0%	4.4%	4.2%
EBIT (INR mn)	55,500	49,420	12.3%	54,056	2.7%	54,091	2.6%	9.4%	9.5%
EBIT margin	17.4%	16.3%	109bp	17.1%	32bp	17.1%	28bp	78bp	82bp
PAT (INR mn)	42,360	38,430	10.2%	43,200	-1.9%	43,020	-1.5%	12.4%	11.9%
EPS (INR)	15.6	14.2	10.2%	15.9	-1.9%	15.9	-1.5%	12.4%	11.9%

Source: Company, JM Financial estimates

2QFY26 result review

Exhibit 2. Key financials

INR mn	1QFY25	2QFY25	3QFY25	4QFY25	FY25	1QFY26	2QFY26
Cons revenues (USD mn)	3,364	3,445	3,533	3,498	13,840	3,545	3,644
<i>Change (QoQ/YoY)</i>	-1.9%	2.4%	2.5%	-1.0%	4.3%	1.3%	2.8%
Cons. revenues (INR m)	2,80,570	2,88,620	298,900	302,460	1,170,550	303,490	319,420
<i>Change (QoQ/YoY)</i>	-1.6%	2.9%	3.6%	1.2%	6.5%	0.3%	5.2%
Direct Costs	1,87,710	1,91,840	196,610	201,990	778,150	205,830	215,380
Gross profit	92,860	96,780	102,290	100,470	392,400	97,660	104,040
Gross margin	33.1%	33.5%	34.2%	33.2%	33.5%	32.2%	32.6%
Total operating expense	34,920	33,090	33,690	35,650	137,350	37,310	38,110
Operating profit (EBITDA)	57,940	63,690	68,600	64,820	255,050	60,350	65,930
EBITDA margin	20.7%	22.1%	23.0%	21.4%	21.8%	19.9%	20.6%
Depreciation & amortization	9,980	10,070	10,390	10,400	40,840	10,930	10,430
EBIT	47,960	53,620	58,210	54,420	214,210	49,420	55,500
EBIT margin	17.1%	18.6%	19.5%	18.0%	18.3%	16.3%	17.4%
Total other income	9,120	3,250	3,110	2,930	18,410	2,470	1,520
Profit before tax	57,080	56,870	61,320	57,350	232,620	51,890	57,020
Provision for tax	14,480	14,500	15,380	14,260	58,620	13,450	14,660
PAT	42,600	42,370	45,940	43,090	174,000	38,440	42,360
<i>Change (QoQ/YoY)</i>	20.6%	10.5%	5.6%	7.9%	10.8%	-9.8%	0.0%
Adjusted basic EPS	15.7	15.6	16.9	15.9	64.1	14.2	15.6
<i>Change (QoQ/YoY)</i>	6.8%	-0.5%	8.4%	-6.2%	10.8%	-10.6%	10.0%

Source: Company, JM Financial

Revenue QoQ cc:

IT Services: 2.6%

ERS: 2.2%

Software: 0.5%

Revenue growth in the quarter was led by services segment. Software dragged overall revenues but grew sequentially

ROW grew 7.4% QoQ (USD), leading growth in the quarter. Europe and North American grew 3% and 2.5% respectively

Exhibit 3. Vertical portfolio

	2Q25	3Q25	4Q25	1Q26	2Q26
Distribution					
Financial Services (BFSI)	20.5%	20.3%	21.1%	21.6%	21.7%
Manufacturing	19.5%	19.1%	18.6%	18.6%	18.3%
Technology and Services	13.1%	13.3%	13.4%	14.0%	14.0%
Telecom, Media, Publishing & Entertainment	12.2%	12.1%	14.7%	14.5%	14.7%
Retail & CPG	9.4%	9.6%	8.6%	8.5%	8.9%
Healthcare	16.0%	15.5%	9.7%	9.7%	9.6%
Public Services	9.1%	9.2%	13.9%	13.1%	12.7%
Revenue (USD mn and QoQ growth)					
Financial Services (BFSI)	638	638	667	697	721
<i>Change</i>	0.0%	0.0%	4.5%	4.4%	3.5%
Manufacturing (including Hi-tech)	1,015	1,019	1,012	1,052	1,073
<i>Change</i>	3.0%	0.3%	-0.7%	3.9%	2.1%
-Technology and Services	408	418	424	452	465
<i>Change</i>	3.2%	2.5%	1.3%	6.6%	3.0%
-Manufacturing	607	601	588	600	608
<i>Change</i>	2.9%	-1.1%	-2.1%	2.0%	1.4%
Telecom, Media, Publishing & Entertainment	377	387	440	423	422
<i>Change</i>	1.6%	2.6%	13.7%	-3.9%	-0.1%
Retail & CPG	299	333	307	313	319
<i>Change</i>	4.6%	11.5%	-8.0%	2.0%	2.0%
Healthcare	498	487	465	468	489
<i>Change</i>	3.1%	-2.2%	-4.6%	0.6%	4.4%
Public Services	287	280	272	274	296
<i>Change</i>	3.5%	-2.3%	-2.8%	0.8%	7.9%

Source: Company, JM Financial

Lifesciences and healthcare (+4.4% QoQ USD) and public services (7.9%) led growth in the quarter

Financial services saw 11.4% YoY cc growth led by an increase in scope of work at a financial services client (Top 10 client). HCLT displaced an incumbent in this scope expansion

Pipeline and deals in retail and CPG to drive growth going forward

HCLT is seeing decision delays in auto sector within the Manufacturing vertical, does not see a recovery in the immediate near term

Exhibit 4. Key manpower metrics

	2Q25	3Q25	4Q25	1Q26	2Q26
Manpower Base					
Total manpower	2,18,621	220,755	223,420	223,151	226,640
Net addition	-780	2,134	2,665	-269	3,489
As % of total Base	-0.4%	1.0%	1.2%	-0.1%	1.6%
Technical	2,04,600	206,517	209,182	208,970	212,412
Support	14,021	14,238	14,238	14,181	14,228
Operating metrics					
Attrition- IT Services (LTM)	12.9%	13.2%	13.0%	12.8%	12.6%

Source: Company, JM Financial

Bookings, pipeline and demand led to addition of employees in the quarter. Revenue per employee increased, it is expected to continue growing as the company transitions from a headcount linked model to an 'AI + people in the mix' model

Exhibit 5. Key client metrics

	2Q25	3Q25	4Q25	1Q26	2Q26
Revenue concentration					
Top 5 Clients	12.1%	12.6%	12.7%	12.6%	12.4%
Top 10 Clients	20.1%	20.3%	20.2%	20.2%	19.9%
Top 20 Clients	30.8%	30.8%	30.4%	29.9%	29.5%
Non-Top 20 clients	69.2%	69.2%	69.6%	70.1%	70.5%
Revenue growth					
Top 5 Clients	8.7%	6.8%	-0.2%	0.5%	1.2%
Top-6 to 10 clients	-0.1%	-1.3%	-3.6%	2.7%	1.4%
Top 10 Clients	5.0%	3.6%	-1.5%	1.3%	1.3%
Top-11 to 20 clients	4.4%	0.6%	-3.8%	-3.6%	1.7%
Top 20 Clients	4.8%	2.5%	-2.3%	-0.3%	1.4%
Non-Top 20	1.4%	2.5%	-0.4%	2.1%	3.4%
Relationship distribution					
USD 1mn+ Clients	952	952	948	956	954
USD 5mn+ Clients	402	398	399	402	406
USD 10mn+ Clients	251	248	251	255	258
USD 20mn+ Clients	137	136	138	144	151
USD 50mn+ Clients	52	53	52	54	54
USD 100mn+ Clients	22	22	22	22	22

Source: Company, JM Financial

Exhibit 6. Guidance Analysis – Guidance implies 0.3%-1.5% CQGR for IT Services**Guidance analysis - Consolidated**

	FY26 revenue - implied			FY26 growth guidance	
	FY25A	Lower	Upper	Lower	Upper
Revenue (CC) USD Mn	13,840	14,256	14,532	5.10%	7.10%
Implied QoQ growth - Lower end	1Q26	2Q26	3Q26	4Q26	FY26E
Revenue (CC) USD mn	3,545	3,644	3,667	3,690	14,546
Growth (q/q)	1.34%	2.79%	0.6%	0.63%	5.1%
Implied QoQ growth - Upper end	1Q26	2Q26	3Q26	4Q26	FY26E
Revenue (CC) USD mn	3,545	3,644	3,758	3,876	14,823
Growth (q/q)	1.34%	2.79%	3.1%	3.13%	7.1%

Guidance analysis - Services

	FY26 revenue - implied			FY26 growth guidance	
	FY25A	Lower	Upper	Lower	Upper
Revenue (CC) USD Mn	12,462	12,961	13,085	6.10%	7.10%
Implied QoQ growth - Lower end	1Q26	2Q26	3Q26	4Q26	FY26E
Revenue (CC) USD mn	3,226	3,323	3,332	3,341	13,222
Growth (q/q)	2.01%	3.02%	0.26%	0.26%	6.1%
Implied QoQ growth - Upper end	1Q26	2Q26	3Q26	4Q26	FY26E
Revenue (CC) USD mn	3,226	3,323	3,373	3,424	13,347
Growth (q/q)	2.01%	3.02%	1.51%	1.51%	7.1%

Note: We have assumed 210bps cc impact for FY26 resulting in USD guidance of 5.1%-7.1% for consol revenue (vs. 3-5% cc as stated) and 6.1%-7.1% for Services (vs. 4-5% cc). Source: Company, JM Financial estimates

Exhibit 7. Products and Platforms: Perpetual license revenue declined due to shift in focus towards subscription

HCL Software Revenue	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Revenue (USD Mn)						
Perpetual License Upfront & Others	36.4	58.2	49.4	34.4	29.0	24.0
Subscription & Support	281.7	267.2	329.4	295.0	282.0	290.0
Professional Services	16.4	16.5	21.3	18.5	19.0	19.0
Total Products & Platform revenue	334.5	341.9	400.1	347.9	330	333.0
% Distribution						
Perpetual License Upfront & Others	10.9%	17.0%	12.3%	9.9%	8.8%	7.2%
Subscription & Support	84.2%	78.2%	82.3%	84.8%	85.4%	87.1%
Professional Services	4.9%	4.8%	5.3%	5.3%	5.8%	5.7%
YoY Growth						
Perpetual License Upfront & Others	1%	90%	4%	9%	-20%	-59%
Subscription & Support	2%	0%	-6%	2%	0%	9%
Professional Services	-15%	-20%	-1%	-14%	16%	15%

Source: Company, JM Financial

Retain ADD, Revised TP of 1,580

We have revised our YoY cc revenue growth estimates by (49)-45 bps over FY26-28E. IT services growth expectations are raised by 0-110bps and ER&D growth estimates are revised by 0-868 bps given performance in 2Q. Products segment growth estimates are revised lower by 73bps for FY26E. EBIT margin assumptions are relatively unchanged at (2)-27bps over FY26-28E. We believe, despite 2Q beat, rebound in margins will be limited given our expectations of high R&D investments. We now build EBIT margin of 17.5% for FY26E (vs. guided range of 17-18%). Changes to our topline and our margin estimates drive (0.7%)-2.1% revision to our EPS estimates over FY26-28E. We continue to value HCLTech at 21x. We maintain ADD with a revised TP of INR 1,580 (from 1,550 earlier).

Exhibit 8. What has changed

	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Exchange rate (INR/USD)	87.67	88.50	88.50	87.59	88.50	88.50	-0.1%	0.0%	0.0%
Revenue growth (CC) - YoY	3.5%	6.0%	7.5%	4.0%	5.5%	7.5%	48bp	-49bp	1bp
Consolidated revenue (USD mn)	14,636	15,558	16,723	14,704	15,558	16,725	0.5%	0.0%	0.0%
Growth in USD revenues (YoY)	5.8%	6.3%	7.5%	6.2%	5.8%	7.5%	49bp	-49bp	1bp
Consolidated revenue (INR mn)	1,283,238	1,376,901	1,479,959	1,287,948	1,376,896	1,480,134	0.4%	0.0%	0.0%
EBITDA margin	20.9%	21.3%	21.3%	20.7%	20.8%	21.1%	-25bp	-47bp	-26bp
EBIT margin	17.4%	17.8%	18.0%	17.5%	17.8%	18.2%	5bp	-2bp	27bp
PAT (INR mn)	175,833	191,768	208,038	174,591	193,652	212,455	-0.7%	1.0%	2.1%
EPS	64.8	70.7	76.7	64.3	71.4	78.3	-0.7%	1.0%	2.1%

Source: JM Financial estimates


Exhibit 9. JMFe vs. Consensus estimates

	Consensus			JMFe			Difference		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales (USD mn)	14,234	15,347	16,526	14,704	15,558	16,725	3.3%	1.4%	1.2%
Sales (INR mn)	1,262,229	1,360,926	1,465,492	1,287,948	1,376,896	1,480,134	2.0%	1.2%	1.0%
EBITDA (INR mn)	266,553	292,632	317,381	266,434	286,848	311,903	0.0%	-2.0%	-1.7%
EBITDA margin (%)	21.1%	21.5%	21.7%	20.7%	20.8%	21.1%	-43bps	-67bps	-58bps
EBIT (INR mn)	220,645	245,388	267,431	225,065	245,162	269,853	2.0%	-0.1%	0.9%
EBIT margin (%)	17.5%	18.0%	18.2%	17.5%	17.8%	18.2%	-1bps	-23bps	-2bps
Net Income (INR mn)	172,964	194,340	211,510	174,591	193,652	212,455	0.9%	-0.4%	0.4%
EPS (INR)	63.8	71.7	77.9	64.3	71.4	78.3	0.9%	-0.4%	0.5%

Source: Visible Alpha, JM Financial


Valuation Charts

Exhibit 10. HCL Tech - PER 24M Fwd, 5 Years




Source: Bloomberg, JM Financial

Exhibit 11. HCL Tech - PER 12M Fwd, 5 Years




Source: Bloomberg, JM Financial

Exhibit 12. HCL Tech - PEG 24M Fwd, 5 Years




Source: Bloomberg, JM Financial

Exhibit 13. HCL Tech - PER Premium/Discount to NSE IT (12M Fwd)




Source: Bloomberg, JM Financial

Exhibit 14. PER differential - HCL Tech over Infosys



Source: Bloomberg, JM Financial

Exhibit 15. HCL Tech - LTM FCF yield



Source: Company, Bloomberg, JM Financial

Financial Tables (Consolidated)

Income Statement (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	10,99,130	11,70,550	12,87,948	13,76,896	14,80,134
Sales Growth	8.3%	6.5%	10.0%	6.9%	7.5%
Other Operating Income	0	0	0	0	0
Total Revenue	10,99,130	11,70,550	12,87,948	13,76,896	14,80,134
Cost of Goods Sold/Op. Exp	7,21,250	7,78,150	8,67,293	9,24,528	9,95,056
Personnel Cost	0	0	0	0	0
Other Expenses	1,35,880	1,37,350	1,54,222	1,65,519	1,73,176
EBITDA	2,42,000	2,55,050	2,66,434	2,86,848	3,11,903
EBITDA Margin	22.0%	21.8%	20.7%	20.8%	21.1%
EBITDA Growth	6.9%	5.4%	4.5%	7.7%	8.7%
Depn. & Amort.	41,730	40,840	41,368	41,687	42,050
EBIT	2,00,270	2,14,210	2,25,065	2,45,162	2,69,853
Other Income	9,400	18,410	9,599	13,434	13,541
Finance Cost	0	0	0	0	0
PBT before Excep. & Forex	2,09,670	2,32,620	2,34,664	2,58,595	2,83,394
Excep. & Forex Inc/Loss(-)	0	0	0	0	0
PBT	2,09,670	2,32,620	2,34,664	2,58,595	2,83,394
Taxes	52,570	58,620	60,033	64,904	70,848
Extraordinary Inc./Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	80	90	40	40	90
Reported Net Profit	1,57,020	1,73,910	1,74,591	1,93,652	2,12,455
Adjusted Net Profit	1,57,020	1,73,910	1,74,591	1,93,652	2,12,455
Net Margin	14.3%	14.9%	13.6%	14.1%	14.4%
Diluted Share Cap. (mn)	2,713.7	2,713.7	2,713.7	2,713.7	2,713.7
Diluted EPS (INR)	57.9	64.1	64.3	71.4	78.3
Diluted EPS Growth	5.7%	10.8%	0.4%	10.9%	9.7%
Total Dividend + Tax	1,69,838	1,95,967	2,02,499	2,35,160	2,54,757
Dividend Per Share (INR)	52.0	60.0	62.0	72.0	78.0

Source: Company, JM Financial

Cash Flow Statement (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Profit before Tax	2,09,670	2,32,610	1,74,631	1,93,692	2,12,545
Depn. & Amort.	41,730	40,840	41,368	41,687	42,050
Net Interest Exp. / Inc. (-)	0	0	0	0	0
Inc (-) / Dec in WCap.	23,050	10,100	-17,967	-5,196	-20,698
Others	-7,850	-18,510	0	0	0
Taxes Paid	0	0	0	0	0
Operating Cash Flow	2,66,600	2,65,040	1,98,033	2,30,183	2,33,897
Capex	-10,480	-11,080	-23,702	-24,429	-26,531
Free Cash Flow	2,56,120	2,53,960	1,74,331	2,05,753	2,07,366
Inc (-) / Dec in Investments	-49,540	-29,700	0	0	0
Others	-14,850	-17,520	-4,380	-4,425	-4,425
Investing Cash Flow	-74,870	-58,300	-28,081	-28,854	-30,956
Inc / Dec (-) in Capital	0	0	0	0	0
Dividend + Tax thereon	-1,40,730	-1,62,500	0	0	0
Inc / Dec (-) in Loans	-1,810	-810	0	0	0
Others	-12,100	-22,300	0	0	0
Financing Cash Flow	-1,54,640	-1,85,610	0	0	0
Inc / Dec (-) in Cash	37,090	21,130	1,69,951	2,01,328	2,02,941
Opening Cash Balance	2,27,120	2,79,880	2,97,380	3,05,462	3,08,895
Closing Cash Balance	2,64,210	3,01,010	4,67,331	5,06,790	5,11,837

Source: Company, JM Financial

Balance Sheet (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Shareholders' Fund	6,82,630	6,96,550	7,05,120	7,04,408	7,05,198
Share Capital	0	0	0	0	0
Reserves & Surplus	6,82,630	6,96,550	7,05,120	7,04,408	7,05,198
Preference Share Capital	0	0	0	0	0
Minority Interest	80	180	240	280	370
Total Loans	23,270	22,910	23,590	23,590	23,565
Def. Tax Liab. / Assets (-)	0	0	0	0	0
Total - Equity & Liab.	7,05,980	7,19,640	7,28,950	7,28,278	7,29,133
Net Fixed Assets	3,22,610	3,32,150	3,30,982	3,17,796	3,06,350
Gross Fixed Assets	49,990	45,600	50,049	52,958	54,820
Intangible Assets	2,72,620	2,86,550	2,80,933	2,64,839	2,51,530
Less: Depn. & Amort.	0	0	0	0	0
Capital WIP	0	0	0	0	0
Investments	3,810	12,970	4,510	4,510	4,510
Current Assets	6,71,350	7,10,320	7,48,143	7,72,387	8,00,702
Inventories	0	0	0	0	0
Sundry Debtors	2,55,210	2,58,420	2,74,513	2,90,468	3,04,137
Cash & Bank Balances	2,79,880	2,97,380	3,05,462	3,08,895	3,16,913
Loans & Advances	0	0	0	0	0
Other Current Assets	1,36,260	1,54,520	1,68,167	1,73,023	1,79,651
Current Liab. & Prov.	2,91,790	3,35,800	3,54,684	3,66,415	3,82,429
Current Liabilities	76,470	91,090	1,00,790	1,00,790	1,00,790
Provisions & Others	2,15,320	2,44,710	2,53,894	2,65,625	2,81,639
Net Current Assets	3,79,560	3,74,520	3,93,459	4,05,972	4,18,273
Total - Assets	7,05,980	7,19,640	7,28,950	7,28,278	7,29,133

Source: Company, JM Financial


Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	14.3%	14.9%	13.6%	14.1%	14.4%
Asset Turnover (x)	1.5	1.5	1.6	1.7	1.8
Leverage Factor (x)	1.1	1.2	1.2	1.2	1.2
RoE	23.5%	25.2%	24.9%	27.5%	30.1%
Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (₹)	251.6	256.7	259.8	259.6	259.9
ROIC	34.6%	38.5%	40.4%	44.0%	49.2%
ROE	23.5%	25.2%	24.9%	27.5%	30.1%
Net Debt/Equity (x)	-0.4	-0.4	-0.4	-0.4	-0.4
P/E (x)	25.8	23.3	23.2	20.9	19.1
P/B (x)	5.9	5.8	5.8	5.8	5.8
EV/EBITDA (x)	15.7	14.8	14.2	13.2	12.1
EV/Sales (x)	3.5	3.2	2.9	2.7	2.5
Debtor days	85	81	78	77	75
Inventory days	0	0	0	0	0
Creditor days	0	0	0	0	0

Source: Company, JM Financial

History of Recommendation and Target Price

Date	Recommendation	Target Price	% Chg.
9-Dec-22	Hold	1,180	
13-Jan-23	Hold	1,190	0.8
21-Apr-23	Hold	1,080	-9.2
13-Jul-23	Hold	1,070	-0.9
13-Oct-23	Hold	1,250	16.8
13-Jan-24	Hold	1,680	34.4
27-Apr-24	Hold	1,480	-11.9
13-Jul-24	Hold	1,500	1.4
29-Aug-24	Hold	1,550	3.3
15-Oct-24	Hold	1,780	14.8
14-Jan-25	Hold	1,830	2.8
23-Apr-25	Hold	1,540	-15.8
15-Jul-25	Hold	1,640	6.5
1-Oct-25		1,550	-5.5

Recommendation History



APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.comCompliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: ashley.johnson@jmfl.comGrievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

New Rating System: Definition of ratings	
Rating	Meaning
BUY	Expected return $\geq$ 15% over the next twelve months.
ADD	Expected return $\geq$ 5% and $<$ 15% over the next twelve months.
REDUCE	Expected return $\geq$ -10% and $<$ 5% over the next twelve months.
SELL	Expected return $<$ -10% over the next twelve months.

Previous Rating System: Definition of ratings	
Rating	Meaning
BUY	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.
HOLD	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.
SELL	Price expected to move downwards by more than 10% from the current market price over the next twelve months.

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.